Depression affects a significant proportion of ex-serving Australian Defence Force personnel, many of whom also manage post-traumatic stress disorder after deployment.
Around 1 in 9 Australian adults experience depression at a given time, yet prevalence is higher among ex-serving ADF members and each veteran cohort exposed to sustained operational demands. Antidepressant medication remains a standard intervention within national guidelines, although some patients report limited response despite adequate trials.
Transcranial magnetic stimulation, delivered as repetitive non-invasive brain stimulation, provides a non-drug option in outpatient psychiatric settings. Clinicians administer TMS using targeted magnetic pulses applied to cortical regions involved in mood regulation, generally without requiring medication changes.
Evidence supports TMS therapy for treatment-resistant major depression. The Department of Veteran Affairs (DVA) may fund eligible Veteran Cardholders for approved TMS treatment when claimed by a psychiatrist under relevant Medicare Benefits Schedule items.
Why Veterans are More Susceptible to Depression
Veterans are more vulnerable to PTSD and depression due to the intense stressors they face during and after military service. Combat exposure often leads to lasting psychological issues, with mental health conditions like PTSD and depression frequently co-occurring.
Chronic stress, hypervigilance, and trauma impact the prefrontal cortex and limbic system, which affects emotional regulation. This makes it difficult for veterans to manage everyday stress.
Post-service, many veterans experience challenges like social isolation, identity loss, and moral injury. These factors intensify the effects of depression, making mental health conditions harder to manage. Conventional treatments may not always provide lasting relief, highlighting the need for specialised care.
How Antidepressants Work
Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly prescribed for the treatment of depression. These medications work by inhibiting the reuptake of serotonin and norepinephrine, which helps regulate mood.
It typically takes 4 to 6 weeks for patients to feel the therapeutic effects. Despite their effectiveness, medications have limitations. Many veterans report common side effects like emotional blunting, fatigue, sexual dysfunction, and weight changes, which can reduce adherence.
For some, severe depression persists even after trying two or more antidepressants. This is known as treatment-resistant depression, which requires alternative therapies to address its complex nature. Veterans also face the issue of polypharmacy, as they may already be managing chronic pain, sleep disorders, or other conditions. This complicates treatment decisions.
How TMS Therapy Works
Repetitive transcranial magnetic stimulation (rTMS) uses electromagnetic coils to deliver magnetic pulses to the left dorsolateral prefrontal cortex (DLPFC), playing a vital role in emotional regulation.
These pulses help to restore neural activity, which is often suppressed in depression. Over time, repeated treatment sessions strengthen synaptic connections and improve the brain’s ability to regulate emotions, leading to better long-term stability.
Each session lasts approximately 20 minutes, typically three to five days a week, over 4 to 7 weeks. It does not require anaesthesia, and patients experience no downtime. Deep transcranial magnetic stimulation (dTMS) reaches deeper structures in the brain, and emerging evidence suggests it may benefit patients with both depression and PTSD.
TMS vs Medication: A Direct Comparison
For veteran depression, TMS versus medication differ mainly in practical terms. TMS is non-invasive and does not usually cause systemic side effects, unlike medication.
TMS may cause local side effects such as scalp discomfort or headaches. Medication often requires daily pills, has potential systemic side effects, and can interact with other treatments.
Efficacy for Treatment-Resistant Cases
For veterans with treatment-resistant depression, options can become limited. Adjusting antidepressants or adding other medications like lithium or atypical antipsychotics may be the next step.
In later treatment steps, switching or combining drugs often leads to remission in only a minority of patients (around 10–25% in large studies). As more treatments are attempted, the likelihood of success with additional trials decreases.
Transcranial magnetic stimulation for depression (TMS) provides an alternative that, in treatment-resistant depression, has shown higher remission rates than simply switching to another antidepressant in several studies.
Neuralia TMS quotes an approximately 60–65% success rate for TMS therapy, a figure considered conservative. This compares favourably with the diminishing returns observed in successive antidepressant trials documented in large studies, such as STAR*D.
Brain stimulation treatment through TMS therapy directly targets mood-regulating brain regions and may offer meaningful benefits for veterans with treatment-resistant depression.
Side Effect Profile
Veterans with comorbid PTSD may experience challenges when undergoing pharmacological management for MDD and PTSD symptoms. Medications can produce systemic effects that extend beyond the central nervous system.
Medications can cause:
- Cognitive dulling
- Libido changes
- Weight gain
- Fatigue
- Gastrointestinal upset
- Cardiovascular concerns
TMS, a non-invasive therapy that uses magnetic pulses, has a different safety profile.
TMS typically involves:
- Localised scalp discomfort or mild headache during early sessions
- Minimal impact on cognition or sexual function
- No known direct hormonal, metabolic, or cardiovascular effects
For the acute treatment of major depression, TMS is generally better tolerated and associated with fewer systemic side effects across a standard course of treatment. Clinical assessment determines suitability before commencing a full course of TMS.
The treatment is not painful, and most patients find it relaxing. No long-term side effects of TMS have been identified, with over 40 years of clinical use supporting its safety record.
Speed of Onset
Antidepressant medication often requires 4 to 8 weeks before a meaningful therapeutic shift becomes apparent. Gradual dose increases can extend that timeline further to balance benefit with tolerability, lengthening the overall treatment process.
Some veterans move through multiple agents across months before stabilising symptoms, delaying functional recovery and return to structured daily routines.
Repetitive stimulation can produce earlier observable change for many patients. Many individuals report measurable mood improvement by weeks 2 or 3 during a structured course. Each TMS treatment session builds on the previous one, and cumulative neural effects consolidate over a 4–6-week programme.
Long-Term Use
Long-term planning differs in TMS vs. medication for Veteran Depression Treatment. Most antidepressants require daily dosing to sustain effect.
Stopping abruptly can trigger discontinuation symptoms that complicate ongoing treatment of depression, leading many veterans to remain on medications and therapy for extended periods to preserve symptom stability.
Repetitive stimulation follows a time-limited structure. In many responders, benefits can persist for a year or more, and in some cases several years, after the final treatment session. When symptoms re-emerge, maintenance TMS may be scheduled to reinforce gains and minimise the need for continuous pharmacological exposure.
Interaction with PTSD
Selective serotonin reuptake inhibitors remain a first-line pharmacological treatment for PTSD within Australian guidelines. Response rates in veterans are often lower than those reported in civilian samples.
Some individuals describe emotional blunting that interferes with engagement in trauma-focused therapy for PTSD, particularly when addressing intrusive memories and hyperarousal.
Repetitive stimulation is designed to target prefrontal and limbic circuits implicated in trauma and mood disorders. Modulating networks involved in the treatment of major depressive disorder may support patients who carry dual diagnoses.
Veterans who receive TMS often do so within an integrated care plan that includes psychotherapy. Each TMS treatment session aims to stabilise mood circuitry while trauma therapy addresses cognitive processing.
Can TMS and Medication Be Used Together?
Many veterans with depression begin care while already taking prescribed antidepressants. Starting transcranial magnetic stimulation therapy generally does not require tapering existing medication before the first appointment.
Research supports combined approaches, and several studies report greater improvement on a validated depression rating scale when stimulation augments pharmacotherapy in treatment-resistant cohorts.
Medication and stimulation influence different neural systems. A coordinated review process allows dose adjustments while tracking response and tolerability across successive weeks. Within veterans affairs pathways, rTMS treatment can complement other treatments, forming part of a larger care plan.
Department of Veterans’ Affairs Funding and Accessing TMS in Australia
Veterans with PTSD and depression often face complex challenges when seeking care. DVA may cover TMS treatment for eligible Veteran Card holders who meet clinical criteria, with claims made under relevant MBS rTMS items. Coverage depends on the veteran’s card status and the presence of medication-resistant major depression, with DVA paying 140% of the MBS fee for qualified individuals.
Access usually involves a GP referral to a psychiatrist, who then assesses suitability and arranges TMS if appropriate. The assessment process screens for contraindications, including epilepsy or a history of seizures, and ferrous (magnetic) metal implants in the head or neck area. These funding pathways help veterans who are suitable for TMS access a non-pharmacological treatment alongside other mental health supports.
For eligible patients with Treatment-Resistant Depression, Medicare may also cover TMS with no out-of-pocket cost. Neuralia TMS became Australia’s first multi-site TMS-specific service to offer a no-gap Medicare option as of March 2023. Veterans should discuss both DVA and Medicare eligibility pathways with their treating psychiatrist.
Who is a Good Candidate for TMS?
Veterans experiencing persistent symptoms of depression despite adequate antidepressant treatment may consider TMS vs. medication for Veteran Depression Treatment. Suitability depends on diagnosis, prior response to medication and medical safety factors identified during specialist review.
- Diagnosis: Confirmed major depressive disorder with inadequate response to at least one antidepressant course.
- Preference: Desire for a non-pharmacological treatment option to reduce reliance on daily medication.
- Comorbidity: Presence of post-traumatic stress disorder, where overlapping neural dysfunction may support consideration of stimulation.
- Safety: Absence of contraindications such as epilepsy or a history of seizures, or ferrous (magnetic) metal implants in the head or neck area.
Neuralia TMS delivers repetitive transcranial magnetic stimulation. Each person completes a detailed assessment followed by an individualised treatment plan shaped by clinical history and current presentation.
Sessions occur on a defined schedule across several weeks, with progress reviewed at regular intervals to guide adjustments where appropriate. Care is coordinated alongside existing mental health supports to maintain continuity throughout the programme.
A full course involves 35 sessions, typically delivered three to five times per week. While this represents a meaningful time commitment, Neuralia TMS offers extended clinic hours before and after standard business hours to accommodate veterans who are working or managing other commitments.
Contact Neuralia TMS to discuss whether TMS therapy aligns with your current treatment goals.
Tms vs. Medication Veteran Depression FAQs
Is TMS only considered after failed multiple medications?
TMS is generally considered after at least one adequate antidepressant course has not provided sufficient relief or has caused limiting side effects.
You do not need to exhaust every medication option. A psychiatrist reviews prior treatments, including dosage and duration, to determine whether TMS is appropriate at your current stage.
Does having PTSD make TMS less effective for depression?
Not necessarily. Many veterans receiving TMS live with both depression and PTSD. The primary target remains major depressive disorder, yet mood improvement can support participation in trauma-focused therapy. PTSD continues to be treated directly through psychotherapy and structured supports.
If TMS works, will I be able to reduce or stop my antidepressant?
Possibly, depending on stability. Some veterans maintain their dose; others reduce it gradually; and some taper under supervision. Medication changes are planned with your psychiatrist after reviewing symptom stability following a full TMS course.
Back to Top: TMS vs Medication for Veteran Depression Treatment
